{
    "clinical_study": {
        "@rank": "16722", 
        "arm_group": {
            "arm_group_label": "nanoparticle albumin-bound paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant chemotherapy of platinum-based nanoparticle albumin-bound paclitaxel in stage \u2161 B and IIIA non-small cell lung cancer"
        }, 
        "brief_summary": {
            "textblock": "platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer\n      (NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and\n      safety than solvent-based paclitaxel.However, the safety and efficacy is uncertain in\n      neoadjuvant therapy."
        }, 
        "brief_title": "Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Non Small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The main purpose of this study is to observe the safety and efficacy of platinum-based\n      albumin-bound paclitaxel regimen in the treatment of non-small cell lung cancer (NSCLC) of\n      stage \u2161 B and IIIA ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.Histological or cytological diagnosis of NSCLC of Stage \u2161 B and IIIA .\n\n        2.18 years or older 3.Performance Status 0 to 2; 4.Appraisable disease; 5.patients can\n        tolerant chemotherapy; 6.Total bilirubin 1.5 x upper limit of normal (ULN); 7.Creatinine\n        clearance 60ml/min (calculated according to Cockcroft-gault formula).\n\n        Exclusion Criteria:\n\n        1.Any systemic anticancer treatment for NSCLC\uff1b2.Local radiotherapy for NSCLC\uff1b3.In this\n        study within five years prior to the start of treatment with other than NSCLC patients\n        with other cancers.4.Any instability in systemic disease; 5.Allergic to paclitaxel or\n        Platinum;6.Pregnant or lactating women;7.Other researchers believe that does not fit into\n        the group"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016209", 
            "org_study_id": "ZYTOP1402"
        }, 
        "intervention": {
            "arm_group_label": "nanoparticle albumin-bound paclitaxel", 
            "description": "Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage \u2161 B and IIIA non-small cell lung cancer", 
            "intervention_name": "nanoparticle albumin-bound paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": "nab-paclitaxel"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 14, 2013", 
        "location": {
            "contact": {
                "email": "doczq.2008@gmail.com", 
                "last_name": "Qiong Zhao, PhD", 
                "phone": "0571-87236802"
            }, 
            "facility": {
                "address": {
                    "city": "Hangzhou", 
                    "country": "China", 
                    "state": "Zhejiang", 
                    "zip": "310003"
                }, 
                "name": "The first affiliated hospital, Zhejiang University"
            }, 
            "investigator": {
                "last_name": "Qiong Zhao, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage \u2161 B and IIIA Non-small Cell Lung Cancer Patients", 
        "other_outcome": {
            "measure": "dynamic circulating tumor cell changes during treatment", 
            "safety_issue": "No", 
            "time_frame": "baseline, 3 weeks and up to progression disease"
        }, 
        "overall_contact": {
            "email": "doczq.2008@gmail.com", 
            "last_name": "Qiong Zhao, PhD", 
            "phone": "0571-87236802"
        }, 
        "overall_official": {
            "affiliation": "The first affiliated hospital, Zhejiang University", 
            "last_name": "Qiong Zhao, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Tumor response rate and Number of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "From date of randomization until the date of progression, assessed up to 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016209"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Zhejiang University", 
            "investigator_full_name": "Qiong Zhao", 
            "investigator_title": "Chief of Department of Thoracic Oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "disease free survival", 
            "safety_issue": "No", 
            "time_frame": "From date of surgery until the date of first documented progression, assessed up to 36 months"
        }, 
        "source": "Zhejiang University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Zhejiang University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}